About 89bio
89bio is a company based in San Francisco (United States) founded in 2018.. 89bio has raised $60 million across 1 funding round from investors including Orbimed, RA Capital and Longitude Capital. The company has 93 employees as of December 31, 2024. 89bio offers products and services including Pegozafermin. 89bio operates in a competitive market with competitors including Rhythm Pharmaceuticals, MannKind Corp, NGM Biopharmaceuticals, Corcept and ViaCyte, among others.
- Headquarter San Francisco, United States
- Employees 93 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name 89Bio, Inc.
-
Annual Revenue
$00as on Dec 31, 2024
-
Net Profit
$-367.08 M-158.16as on Dec 31, 2024
-
EBITDA
$-384.62 M-154.83as on Dec 31, 2024
-
Total Equity Funding
$60 M (USD)
in 1 rounds
-
Latest Funding Round
$60 M (USD), Series A
Oct 25, 2018
-
Investors
Orbimed
& 3 more
-
Employee Count
93
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of 89bio
89bio is a publicly listed company on the NASDAQ with ticker symbol ETNB in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of 89bio
89bio offers a comprehensive portfolio of products and services, including Pegozafermin. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Investigational drug for treating MASH and severe hypertriglyceridemia in patients.
Unlock access to complete
Unlock access to complete
Funding Insights of 89bio
89bio has successfully raised a total of $60M through 1 strategic funding round. The most recent funding activity was a Series A round of $60 million completed in October 2018. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 1
- Last Round Series A — $60.0M
-
First Round
First Round
(25 Oct 2018)
- Investors Count 4
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct, 2018 | Amount | Series A - 89bio | Valuation | Orbimed , Longitude Capital |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in 89bio
89bio has secured backing from 4 investors, including venture fund and institutional investors. Prominent investors backing the company include Orbimed, RA Capital and Longitude Capital. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields.
|
Founded Year | Domain | Location | |
|
Private equity firm focused on life science sector
|
Founded Year | Domain | Location | |
|
Pontifax Venture Capital is focused on life sciences investments.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by 89bio
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - 89bio
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
89Bio Comparisons
Competitors of 89bio
89bio operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Rhythm Pharmaceuticals, MannKind Corp, NGM Biopharmaceuticals, Corcept and ViaCyte, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Developer of peptide therapeutics for the treatment of rare genetic deficiencies
|
|
| domain | founded_year | HQ Location |
Developer of small-molecule drugs
|
|
| domain | founded_year | HQ Location |
Biologics are developed for cardio-metabolic and liver diseases.
|
|
| domain | founded_year | HQ Location |
Developer of cortisol modulators for the treatment of various diseases
|
|
| domain | founded_year | HQ Location |
Cell therapy for diabetes is developed from stem cells.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on 89Bio
Frequently Asked Questions about 89bio
When was 89bio founded?
89bio was founded in 2018.
Where is 89bio located?
89bio is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
Who is the current CEO of 89bio?
Rohan Palekar is the current CEO of 89bio.
Is 89bio a funded company?
89bio is a funded company, having raised a total of $60M across 1 funding round to date. The company's 1st funding round was a Series A of $60M, raised on Oct 25, 2018.
How many employees does 89bio have?
As of Dec 31, 2024, the latest employee count at 89bio is 93.
What does 89bio do?
89bio is developing therapies for treating nonalcoholic steatohepatitis (NASH) and other liver and metabolic disorders. The lead candidate is BIO89-100, which is a long-acting glycopegylated fibroblast growth factor 21 analog used for treating NASH. They have developed the product from their proprietary glycopegylation technology. The candidate is in phase I clinical trial.
Who are the top competitors of 89bio?
89bio's top competitors include Rhythm Pharmaceuticals, MannKind Corp and Corcept.
What products or services does 89bio offer?
89bio offers Pegozafermin.
Is 89bio publicly traded?
Yes, 89bio is publicly traded on NASDAQ under the ticker symbol ETNB.
Who are 89bio's investors?
89bio has 4 investors. Key investors include Orbimed, RA Capital, Longitude Capital, and Pontifax Venture Capital.
What is 89bio's ticker symbol?
The ticker symbol of 89bio is ETNB on NASDAQ.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.